Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-896.63%
operating margin TTM
-986.94%
revenue TTM
86.20 Million
revenue per share TTM
1.02$
valuation ratios | |
|---|---|
| pe ratio | -2.71 |
| peg ratio | -0.32 |
| price to book ratio | 24.30 |
| price to sales ratio | 24.01 |
| enterprise value multiple | -3.23 |
| price fair value | 24.30 |
profitability ratios | |
|---|---|
| gross profit margin | 266.59% |
| operating profit margin | -986.94% |
| pretax profit margin | -896.63% |
| net profit margin | -896.63% |
| return on assets | -49.55% |
| return on equity | -658.91% |
| return on capital employed | -79.81% |
liquidity ratios | |
|---|---|
| current ratio | 2.21 |
| quick ratio | 2.21 |
| cash ratio | 1.83 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 25.80 |
| days of payables outstanding | -194.15 |
| cash conversion cycle | 219.94 |
| receivables turnover | 14.15 |
| payables turnover | -1.88 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.29 |
| debt equity ratio | 5.25 |
| long term debt to capitalization | 0.78 |
| total debt to capitalization | 0.84 |
| interest coverage | -1,490.85 |
| cash flow to debt ratio | -1.52 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.48 |
| cash per share | 0.70 |
| operating cash flow per share | -0.48 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -1.52 |
| short term coverage ratios | -4.85 |
| capital expenditure coverage ratio | -247.57 |
Frequently Asked Questions
When was the last time Innate Pharma S.A. (NASDAQ:IPHA) reported earnings?
Innate Pharma S.A. (IPHA) published its most recent earnings results on 30-06-2025.
What is Innate Pharma S.A.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Innate Pharma S.A. (NASDAQ:IPHA)'s trailing twelve months ROE is -658.91%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Innate Pharma S.A. (IPHA) currently has a ROA of -49.55%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IPHA's net profit margin stand at?
IPHA reported a profit margin of -896.63% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IPHA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.21 in the most recent quarter. The quick ratio stood at 2.21, with a Debt/Eq ratio of 5.25.